@phdthesis{Kalb2021, author = {Kalb, Jacqueline}, title = {The role of BRCA1 and DCP1A in the coordination of transcription and replication in neuroblastoma}, doi = {10.25972/OPUS-24871}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-248711}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2021}, abstract = {The deregulation of the MYC oncoprotein family plays a major role in tumorigenesis and tumour maintenance of many human tumours. Because of their structure and nuclear localisation, they are defined as undruggable targets which makes it difficult to find direct therapeutic approaches. An alternative approach for targeting MYC-driven tumours is the identification and targeting of partner proteins which score as essential in a synthetic lethality screen. Neuroblastoma, an aggressive entity of MYCN-driven tumours coming along with a bad prognosis, are dependent on the tumour suppressor protein BRCA1 as synthetic lethal data showed. BRCA1 is recruited to promoter regions in a MYCN-dependent manner. The aim of this study was to characterise the role of BRCA1 in neuroblastoma with molecular biological methods. BRCA1 prevents the accumulation of RNA Polymerase II (RNAPII) at the promoter region. Its absence results in the formation of DNA/RNA-hybrids, so called R-loops, and DNA damage. To prevent the accumulation of RNAPII, the cell uses DCP1A, a decapping factor known for its cytoplasmatic and nuclear role in mRNA decay. It is the priming factor in the removal of the protective 5'CAP of mRNA, which leads to degradation by exonucleases. BRCA1 is necessary for the chromatin recruitment of DCP1A and its proximity to RNAPII. Cells showed upon acute activation of MYCN a higher dependency on DCP1A. Its activity prevents the deregulation of transcription and leads to proper coordination of transcription and replication. The deregulation of transcription in the absence of DCP1A results in replication fork stalling and leads to activation of the Ataxia telangiectasia and Rad3 related (ATR) kinase. The result is a disturbed cell proliferation to the point of increased apoptosis. The activation of the ATR kinase pathway in the situation where DCP1A is knocked down and MYCN is activated, makes those cells more vulnerable for the treatment with ATR inhibitors. In summary, the tumour suppressor protein BRCA1 and the decapping factor DCP1A, mainly known for its function in the cytoplasm, have a new nuclear role in a MYCN-dependent context. This study shows their essentiality in the coordination of transcription and replication which leads to an unrestrained growth of tumour cells if uncontrolled.}, subject = {Neuroblastom}, language = {en} } @phdthesis{Mak2020, author = {Mak, Ka Yan}, title = {TFIIIC subunits employ different modes of action for regulating N-MYC}, doi = {10.25972/OPUS-18596}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-185969}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2020}, abstract = {Amplification of N-MYC is a poor prognostic and survival marker of neuroblastoma. To broaden the scope of knowledge in N-MYC cancer biology, interactors of N-MYC should be investigated. TFIIIC complex was identified as a new protein interacting partner of N-MYC. TFIIIC is a core component of RNAPIII transcription machinery which is important for the synthesis of tRNA genes. TFIIIC recognizes and binds to B-box located internal of tRNA genes which subsequently initiate the RNAPIII transcription process. Apart from the role in RNAPIII transcription machinery, TFIIIC is an architectural protein. TFIIIC binds to thousands of sites across the genome without RNAPIII and TFIIIB. These binding loci are known as Extra TFIIIC (ETC) sites at which TFIIIC perform its role in genome organization. However, knowledge of TFIIIC is mostly restricted to studies conducted in yeasts, the exact function of TFIIIC and how it regulates N-MYC remains to be elucidated. To obtain a better overview about TFIIIC functions, two TFIIIC subunits (TFIIIC5 and TFIIIC2) which represent sub-complexes A and B were chosen for investigation. ChIP-seq experiment of RNAPIII transcription machinery was performed. It showed that both TFIIIC subunits functioned together as a complex. Next, joint binding sites of two TFIIIC subunits and N-MYC were identified. The data revealed that co-occupancies between N-MYC and TFIIIC subunits had different preference on genomic distribution. Furthermore, TFIIIC5 exhibited strong binding association with architectural proteins RAD21 and CTCF whereas TFIIIC2 was only modestly enriched with these two proteins. Both TFIIIC subunits showed equal but weak enrichment with accessory protein CAPH2. Despite the weak association with other architectural proteins, TFIIIC2 binds preferentially to repetitive elements SINE. In order to understand how TFIIIC5 affects other architectural proteins in chromatin binding, cells were depleted of TFIIIC protein upon doxycycline induction of shRNA. N-MYC binding was not affected. Yet, 50\% reduction of RAD21 binding to joint N-MYC/TFIIIC sites was noticed. CAPH2 binding was increased at some joint sites while some did not respond. Lastly, CTCF did not show changes in binding under the effect of TFIIIC5 knockdown. In summary, the data indicated TFIIIC subunits from different sub-complexes diverge in functions other than tRNA synthesis. The association of TFIIIC5 with architectural proteins and TFIIIC2 with SINE elements were suggested to be distinct mechanisms to regulate N-Myc directly or indirectly.}, language = {en} } @phdthesis{Carstensen2018, author = {Carstensen, Anne Carola}, title = {Identification of novel N-MYC interacting proteins reveals N-MYC interaction with TFIIIC}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-143658}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2018}, abstract = {N-MYC is a member of the human MYC proto-oncogene family, which comprises three transcription factors (C-, N- and L-MYC) that function in multiple biological processes. Deregulated expression of MYC proteins is linked to tumour initiation, maintenance and progression. For example, a large fraction of neuroblastoma displays high N-MYC levels due to an amplification of the N-MYC encoding gene. MYCN-amplified neuroblastoma depend on high N-MYC protein levels, which are maintained by Aurora-A kinase. Aurora-A interaction with N-MYC interferes with degradation of N-MYC via the E3 ubiquitin ligase SCFFBXW7. However, the underlying mechanism of Aurora-A-mediated stabilisation of N-MYC remains to be elucidated. To identify novel N-MYC interacting proteins, which could be involved in N-MYC stabilisation by Aurora-A, a proteomic analysis of purified N-MYC protein complexes was conducted. Since two alanine mutations in MBI of N-MYC, T58A and S62A (N-MYC mut), disable Aurora-A-mediated stabilisation of N-MYC, N-MYC protein complexes from cells expressing either N-MYC wt or mut were analysed. Proteomic analysis revealed that N-MYC interacts with two deubiquitinating enzymes, USP7 and USP11, which catalyse the removal of ubiquitin chains from target proteins, preventing recognition by the proteasome and subsequent degradation. Although N-MYC interaction with USP7 and USP11 was confirmed in subsequent immunoprecipitation experiments, neither USP7, nor USP11 was shown to be involved in the regulation of N-MYC stability. Besides USP7/11, proteomic analyses identified numerous additional N-MYC interacting proteins that were not described to interact with MYC transcription factors previously. Interestingly, many of the identified N-MYC interaction partners displayed a preference for the interaction with N-MYC wt, suggesting a MBI-dependent interaction. Among these were several proteins, which are involved in three-dimensional organisation of chromatin domains and transcriptional elongation by POL II. Not only the interaction of N-MYC with proteins functioning in elongation, such as the DSIF component SPT5 and the PAF1C components CDC73 and CTR9, was validated in immunoprecipitation experiments, but also with the POL III transcription factor TFIIIC and topoisomerases TOP2A/B. ChIP-sequencing analysis of N-MYC and TFIIIC subunit 5 (TFIIIC5) revealed a large number of joint binding sites in POL II promoters and intergenic regions, which are characterised by the presence of a specific motif that is highly similar to the CTCF motif. Additionally, N-MYC was shown to interact with the ring-shaped cohesin complex that is known to bind to CTCF motifs and to assist the insulator protein CTCF. Importantly, individual ChIP experiments demonstrated that N-MYC, TFIIIC5 and cohesin subunit RAD21 occupy joint binding sites comprising a CTCF motif. Collectively, the results indicate that N-MYC functions in two biological processes that have not been linked to MYC biology previously. Furthermore, the identification of joint binding sites of N-MYC, TFIIIC and cohesin and the confirmation of their interaction with each other suggests a novel function of MYC transcription factors in three-dimensional organisation of chromatin.}, subject = {Biologie}, language = {en} } @phdthesis{Roeschert2021, author = {R{\"o}schert, Isabelle}, title = {Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma}, doi = {10.25972/OPUS-24303}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-243037}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2021}, abstract = {Neuroblastoma is the most abundant, solid, extracranial tumor in early childhood and the leading cause of cancer-related childhood deaths worldwide. Patients with high-risk neuroblastoma often show MYCN-amplification and elevated levels of Aurora-A. They have a low overall survival and despite multimodal therapy options a poor therapeutic prognosis. MYCN-amplified neuroblastoma cells depend on Aurora-A functionality. Aurora-A stabilizes MYCN and prevents it from proteasomal degradation by competing with the E3 ligase SCFFBXW7. Interaction between Aurora-A and MYCN can be observed only in S phase of the cell cycle and activation of Aurora-A can be induced by MYCN in vitro. These findings suggest the existence of a profound interconnection between Aurora-A and MYCN in S phase. Nevertheless, the details remain elusive and were investigated in this study. Fractionation experiments show that Aurora-A is recruited to chromatin in S phase in a MYCN-dependent manner. Albeit being unphosphorylated on the activating T288 residue, Aurora-A kinase activity was still present in S phase and several putative, novel targets were identified by phosphoproteomic analysis. Particularly, eight phosphosites dependent on MYCN-activated Aurora-A were identified. Additionally, phosphorylation of serine 10 on histone 3 was verified as a target of this complex in S phase. ChIP-sequencing experiments reveal that Aurora-A regulates transcription elongation as well as histone H3.3 variant incorporation in S phase. 4sU-sequencing as well as immunoblotting demonstrated that Aurora-A activity impacts splicing. PLA measurements between the transcription and replication machinery revealed that Aurora-A prevents the formation of transcription-replication conflicts, which activate of kinase ATR. Aurora-A inhibitors are already used to treat neuroblastoma but display dose-limiting toxicity. To further improve Aurora-A based therapies, we investigated whether low doses of Aurora-A inhibitor combined with ATR inhibitor could increase the efficacy of the treatment albeit reducing toxicity. The study shows that the combination of both drugs leads to a reduction in cell growth as well as an increase in apoptosis in MYCN-amplified neuroblastoma cells, which is not observable in MYCN non-amplified neuroblastoma cells. This new approach was also tested by a collaboration partner in vivo resulting in a decrease in tumor burden, an increase in overall survival and a cure of 25\% of TH-MYCN mice. These findings indicate indeed a therapeutic window for targeting MYCN-amplified neuroblastoma.}, subject = {Neuroblastom}, language = {en} }